(Total Views: 550)
Posted On: 08/28/2020 10:50:21 AM
Post# of 72447
My response to a poster elsewhere who thought too much to do was being made regarding CV in comparison to OM P3 trial:
The OM P3 will be important to IPIX, but CV dwarfs it in what it should be able to do to advance IPIX. Not knocking OM, but CV is the homerun hitter compared to OM being a bunt single hitter.
CV and its testing is what is going to provide many, many opportunities for Brilacidin to be tested across many, many areas of medicine at the top universities, labs, BPs (complementary to their drugs), and non-USA sites.
It will lead Brilacidin into lung, kidney, head, and many other areas of medical need whose yearly revenues are over 100 times as large as OM. It also puts Brilacidin on the map of governmental medical agencies to include BARDA, INH, DOD, and others.
With the addition of Dr. DeGrado, I believe we have also opened up possibilities for numerous other uses for Brilacidin. Cannot say enough how important for the company adding Dr. D to our scientific advisor team will prove to be.
It's all good for IPIX from my vantage point.
The OM P3 will be important to IPIX, but CV dwarfs it in what it should be able to do to advance IPIX. Not knocking OM, but CV is the homerun hitter compared to OM being a bunt single hitter.
CV and its testing is what is going to provide many, many opportunities for Brilacidin to be tested across many, many areas of medicine at the top universities, labs, BPs (complementary to their drugs), and non-USA sites.
It will lead Brilacidin into lung, kidney, head, and many other areas of medical need whose yearly revenues are over 100 times as large as OM. It also puts Brilacidin on the map of governmental medical agencies to include BARDA, INH, DOD, and others.
With the addition of Dr. DeGrado, I believe we have also opened up possibilities for numerous other uses for Brilacidin. Cannot say enough how important for the company adding Dr. D to our scientific advisor team will prove to be.
It's all good for IPIX from my vantage point.
(6)
(0)
